5:42 PM
 | 
Sep 23, 2009
 |  BC Extra  |  Company News

NICE backs Sutent, Stelara, Alimta

The U.K.'s NICE issued guidances recommending the use of Sutent sunitinib from Pfizer Inc. (NYSE:PFE); Stelara ustekinumab from Johnson & Johnson (NYSE:JNJ); and Alimta pemetrexed from Eli Lilly and Co. (NYSE:LLY). All...

Read the full 168 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >